ReviewDiabetes, obesity & metabolism2018
Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
Review in Diabetes, obesity & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04841096 (Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.Diabetes care · 2026Guideline
- Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.European heart journal · 2021Trial
- Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.The Journal of clinical endocrinology and metabolism · 2020Trial
- The role of bempedoic acid in the management of dyslipidaemia in people with diabetes: an expert opinion of Italian diabetologists.Cardiovascular diabetology · 2026Review
- Treatment Initiation and Modification Among Patients Diagnosed With Dyslipidemia: Prevalence and Associated Factors.Journal of lipid and atherosclerosis · 2026Article
- [Cardiovascular diseases and heart failure in diabetes: diagnostics and management (Update 2026)].Wiener klinische Wochenschrift · 2026Review
- Article
- Whole-exome sequencing in obstructive coronary artery disease identifies rare and novel variants in cardiac arrhythmia and pulmonary arterial hypertension-associated genes.Biomolecules & biomedicine · 2026Article
- The Impact of the Multidisciplinary Team on Medication Adherence in Type 2 Diabetes: A Narrative Review.Journal of multidisciplinary healthcare · 2026Review
- Article
- Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East.Advances in therapy · 2025Review
- Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care - The countrywide cross-sectional AUSTRO-PROFIT study.Diabetes, obesity & metabolism · 2025Article
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.Diabetes care · 2025 · on this mapReview
- The association between dietary patterns and cardiovascular disease risk factors in Iranian adults: a cross-sectional study.BMC research notes · 2024Article
- Insulin Resistance in Long COVID-19 Syndrome.Journal of personalized medicine · 2024Article
- The interplay of aging, adipose tissue, and COVID-19: a potent alliance with implications for health.GeroScience · 2024Review
- Treatment intensification and therapeutic inertia of antihypertensive therapy among patients with type 2 diabetes and hypertension with uncontrolled blood pressure.Scientific reports · 2024Article
- Developmental Impacts of Epigenetics and Metabolism in COVID-19.Journal of developmental biology · 2024Review
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.Diabetes care · 2024 · on this mapReview
- Therapeutic inertia in type 2 diabetes mellitus: a fine line between advancing and de-intensifying.Nature reviews. Endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is a major cause of morbidity and mortality globally and the largest contributor to healthcare costs. There is good evidence that management of risk factors such as blood pressure, dyslipidaemia and glucose can lead to improved microvascular and macrovascular complications in individuals with type 2 diabetes mellitus. Legacy effect is a phenomenon used to describe the prolonged benefits of glucose, blood pressure or lipid control in individuals with cardiovascular disease, diabetes or in primary prevention of cardiovascular disease by early risk factor control. There is now also good quality evidence on the legacy benefits of multifactorial risk factor interventions on renal, cardiovascular and mortality outcomes. Despite this robust evidence, therapeutic inertia is widespread in the management of these risk factors in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.